Medicaid

Pharmalot

Most state Medicaid programs continue to restrict access to hepatitis C medicines

By Ed Silverman

Intermountain Healthcare - central pharmacy

Pharmalot

A murky approach to tracking 340B drugs and Medicaid may yield double discounts in some states

By Ed Silverman

Pharmalot

Avanir to pay $116 million to settle bribery charges, while two docs and former sales reps are indicted

By Ed Silverman

Pharmalot

Mylan pays $30 million to settle charges of misleading investors over probe into EpiPen Medicaid rebates

By Ed Silverman

Pharmalot

Few Americans took obesity drugs thanks to doctor doubts and spotty insurance

By Ed Silverman

First Opinion

Grassley: For Medicaid, greater transparency will open the door to better value and outcomes

By Chuck Grassley

Pharmalot

Massachusetts lawmakers approve compromise bill to lower Medicaid drug spending

By Ed Silverman

Pharmalot

Pharmalittle: Trump abandons rebate rule; biotechs fume at Mass. governor’s plan to lower drug prices

By Ed Silverman

Pharmalot

Reckitt will pay $1.4 billion to settle federal probes into marketing of opioid-addiction treatment

By Ed Silverman

Health

‘Sickle cell needs more funding’: An 18-year-old patient advocate calls on Washington to improve children’s health care

By Ruth Hailu

Business

Drug-pricing watchdog group is ‘mouse that roared’

By Jonathan Saltzman — Boston Globe

Pharmalot

Pharmalittle: Pfizer to buy Array for $11 billion, Teva settlement in Oklahoma may hit a new snag

By Ed Silverman

Health Tech

5 names to know at Uber and Lyft: the key players behind ride-sharing’s move into health care

By Megan Thielking

Pharmalot

Pharmalittle: Lawmakers push bill to punish opioid execs; Novartis will have ‘enormous leverage’ pricing its SMA drug

By Ed Silverman

Pharmalot

Mallinckrodt sues CMS over Medicaid rebates for its pricey Acthar Gel medicine

By Ed Silverman

Pharmalot

Seeking to contain drug costs, CMS may have ‘killed’ a PBM billing practice

By Ed Silverman

Pharmalot

Pharmalittle: Surprise FDA approval may dampen storm over pricey drug; should the U.S. adopt reference pricing?

By Ed Silverman

Pharmalot

Pharmalittle: Ending Medicare and Medicaid rebates will boost drug spending

By Ed Silverman

Pharmalot

Pharmalittle: FDA approves Sanofi dengue vaccine; Merck boosts measles vaccine production

By Ed Silverman

Pharmalot

State attorneys general sharply criticize a government task force over opioid prescribing

By Ed Silverman

Pharmalot

Pharmalittle: Allergan shareholders nix proposal to split CEO and chairman roles; FDA orders warnings for sleeping pills

By Ed Silverman

Biotech

MassBio’s push to soften state drug-price legislation produces plenty of drama

By Jon Chesto — Boston Globe

Pharmalot

Pharmalittle: Medicare proposes boosting payments for CAR-T drugs; Sacklers want to settle opioid suits

By Ed Silverman

Pharmalot

Lawmakers ask the Trump administration to investigate PBM pricing practices

By Ed Silverman

Pharmalot

Indivior charged with conducting multibillion-dollar fraud to boost opioid-treatment sales

By Ed Silverman

Medicaid covers sick or dying children. But it takes ‘going to battle’ to get it

Hopewell House hospice has closed. You should care about that

Mass. governor — and one-time insurance executive — eyes a legacy-defining revamp of state’s health care

Pharmalittle: Five companies offer $50 billion deal to settle opioid suits; FDA approves record number of generics

Most state Medicaid programs continue to restrict access to hepatitis C medicines

A murky approach to tracking 340B drugs and Medicaid may yield double discounts in some states

Avanir to pay $116 million to settle bribery charges, while two docs and former sales reps are indicted

Mylan pays $30 million to settle charges of misleading investors over probe into EpiPen Medicaid rebates

Few Americans took obesity drugs thanks to doctor doubts and spotty insurance

Grassley: For Medicaid, greater transparency will open the door to better value and outcomes

Massachusetts lawmakers approve compromise bill to lower Medicaid drug spending

Pharmalittle: Trump abandons rebate rule; biotechs fume at Mass. governor’s plan to lower drug prices

Reckitt will pay $1.4 billion to settle federal probes into marketing of opioid-addiction treatment

‘Sickle cell needs more funding’: An 18-year-old patient advocate calls on Washington to improve children’s health care

Drug-pricing watchdog group is ‘mouse that roared’

Pharmalittle: Pfizer to buy Array for $11 billion, Teva settlement in Oklahoma may hit a new snag

5 names to know at Uber and Lyft: the key players behind ride-sharing’s move into health care

Pharmalittle: Lawmakers push bill to punish opioid execs; Novartis will have ‘enormous leverage’ pricing its SMA drug

Mallinckrodt sues CMS over Medicaid rebates for its pricey Acthar Gel medicine

Seeking to contain drug costs, CMS may have ‘killed’ a PBM billing practice

Pharmalittle: Surprise FDA approval may dampen storm over pricey drug; should the U.S. adopt reference pricing?

Pharmalittle: Ending Medicare and Medicaid rebates will boost drug spending

Pharmalittle: FDA approves Sanofi dengue vaccine; Merck boosts measles vaccine production

State attorneys general sharply criticize a government task force over opioid prescribing

Pharmalittle: Allergan shareholders nix proposal to split CEO and chairman roles; FDA orders warnings for sleeping pills

MassBio’s push to soften state drug-price legislation produces plenty of drama

Pharmalittle: Medicare proposes boosting payments for CAR-T drugs; Sacklers want to settle opioid suits

Lawmakers ask the Trump administration to investigate PBM pricing practices

Indivior charged with conducting multibillion-dollar fraud to boost opioid-treatment sales